

# 4 Year Follow-Up Results Checkmate 214

nivolumab combined with ipilimumab versus sunitinib

in previously untreated advanced or metastatic renal cell carcinoma


source : Albiges L, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020 Nov;5(6):e001079.



**1096**  
Patients




**186**  
Trial Sites




**27**  
Countries

## Trial Design



## Patients with favourable risk


Objective  
Response Rate  
(ORR)




Progression  
Free Survival  
(PFS)




Complete  
Response



Median  
Overall Survival




Duration  
of Response:




## Patients with intermediate/poor risk


Objective  
Response Rate  
(ORR)




Progression  
Free Survival  
(PFS)




Median  
Overall  
Survival



Complete  
Response



Duration of  
Response:



## Side effects all treated patients

Grade 3 or  
Grade 4

